Physician profile
Max Noel
NPI 1376513739
$543.30
in general payments reported to CMS, 2019-2025
11 companies · $27.00 in 2025
The $27.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.08 · 2021: $199 · 2022: $194 · 2023: $29.64 · 2024: $51.00 · 2025: $27.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $166.69 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $67.36 | 2020-2024 | Farxiga |
| Exact Sciences Corporation | $62.19 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $57.31 | 2021-2022 | |
| Daiichi Sankyo INC. | $46.54 | 2022 | |
| Merck Sharp & Dohme LLC | $32.66 | 2020-2021 | |
| Lilly USA, LLC | $29.87 | 2021 | |
| Amgen INC. | $27.00 | 2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $21.06 | 2021 | |
| Horizon Therapeutics Plc | $16.53 | 2022 | |
| Viiv Healthcare Company | $16.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Noel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.